Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?

por Yap, Timothy A, Swanton, Charles, de Bono, Johann S
Publicado 2012

Reappraisal of glucocorticoids in castrate-resistant prostate cancer

por Sartor, Oliver, Parker, Christopher C, de Bono, Johann
Publicado 2014

The future of cytotoxic therapy: selective cytotoxicity based on biology is the key

por de Bono, Johann S, Tolcher, Anthony W, Rowinsky, Eric K
Publicado 2003

The promise of circulating tumor cell analysis in cancer management

por Mateo, Joaquin, Gerlinger, Marco, Rodrigues, Daniel Nava, de Bono, Johann S
Publicado 2014

SOX9 is a driver of aggressive prostate cancer by promoting invasion, cell fate and cytoskeleton alterations and epithelial to mesenchymal transition

por Francis, Jeffrey C., Capper, Amy, Ning, Jian, Knight, Eleanor, de Bono, Johann, Swain, Amanda
Publicado 2018

Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles

por Nanou, Afroditi, Crespo, Mateus, Flohr, Penny, De Bono, Johann S., Terstappen, Leon W. M. M.
Publicado 2018

AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification

por Sowalsky, Adam G., Sharp, Adam, Trostel, Shana Y., de Bono, Johann S., Plymate, Stephen R.
Publicado 2020

Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to b...

por A’Hern, Roger, DeBono, Johann, Sandhu, Shahneen, Kalaitzaki, Eletheria, Usdin, Martine, Hall, Emma E
Publicado 2011

Perceptions and Referral Trends into Phase I Oncology Trials: Results of a Clinical Survey

por Brunetto, Andre, Olmos, David, Arkenau, Hendrik-Tobias, Tan, Daniel, Yap, Timomy, de Bono, Johann, Barriuso, Jorge, Kaye, Stan
Publicado 2011

Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer

por Westaby, Daniel, Jimenez-Vacas, Juan M., Padilha, Ana, Varkaris, Andreas, Balk, Steven P., de Bono, Johann S., Sharp, Adam
Publicado 2021

Unbiased and Automated Identification of a Circulating Tumour Cell Definition That Associates with Overall Survival

por Ligthart, Sjoerd T., Coumans, Frank A. W., Attard, Gerhardt, Mulick Cassidy, Amy, de Bono, Johann S., Terstappen, Leon W. M. M.
Publicado 2011

RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses

por Dolly, Saoirse O, Gurden, Mark D, Drosopoulos, Konstantinos, Clarke, Paul, de Bono, Johann, Kaye, Stan, Workman, Paul, Linardopoulos, Spiros
Publicado 2017

A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic

por Tiu, Crescens, Shinde, Rajiv, Yap, Christina, Rao Baikady, Bindumalini, Banerji, Udai, Minchom, Anna R, de Bono, Johann S, Lopez, Juanita S
Publicado 2020

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

por Ameratunga, Malaka, Braña, Irene, Bono, Petri, Postel-Vinay, Sophie, Plummer, Ruth, Aspegren, John, Korjamo, Timo, Snapir, Amir, de Bono, Johann S
Publicado 2020

Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular Features

por Perez-Lopez, Raquel, Nava Rodrigues, Daniel, Figueiredo, Ines, Mateo, Joaquin, Collins, David J., Koh, Dow-Mu, de Bono, Johann S., Tunariu, Nina
Publicado 2018

Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study

por Delanoy, Nicolas, Robbrecht, Debbie, Eisenberger, Mario, Sartor, Oliver, de Wit, Ronald, Mercier, Florence, Geffriaud-Ricouard, Christine, de Bono, Johann, Oudard, Stéphane
Publicado 2021

Post Hoc Health‐Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies

por Thiery‐Vuillemin, Antoine, Fizazi, Karim, Sartor, Oliver, Oudard, Stéphane, Bury, Denise, Ozatilgan, Ayse, Poole, Elizabeth M., Eisenberger, Mario, de Bono, Johann
Publicado 2021

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy

por Dolly, Saoirse O, Migali, Cristina, Tunariu, Nina, Della-Pepa, Chiara, Khakoo, Shelize, Hazell, Steve, de Bono, Johann S, Kaye, Stanley B, Banerjee, Susana
Publicado 2017

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors

por Spicer, James, Irshad, Sheeba, Ang, Joo Ern, Enting, Deborah, Kristeleit, Rebecca, Uttenreuther-Fischer, Martina, Pemberton, Karine, Pelling, Katy, Schnell, David, de Bono, Johann
Publicado 2016

Neutropenia, neutrophilia, and neutrophil–lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer

por Meisel, Alexander, de Wit, Ronald, Oudard, Stephane, Sartor, Oliver, Stenner-Liewen, Frank, Shun, Zhenming, Foster, Meredith, Ozatilgan, Ayse, Eisenberger, Mario, de Bono, Johann S.
Publicado 2022